Multibagger Selection: Perplexity's picks
Perplexity picked MAZE, ETON, AAPG, TPC, GPOR with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Perplexity |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | MAZE | — | 62% | — | — |
| 2 | ETON | — | 58% | — | — |
| 3 | AAPG | — | 55% | — | — |
| 4 | TPC | — | 55% | — | — |
| 5 | GPOR | — | 50% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +3.39% | +4.29% | 1.22x | 0 |
The model's market view
The environment favors companies with identifiable commercialization, backlog, regulatory, or profitability catalysts rather than broad multiple expansion. Small and mid-cap candidates with strong balance sheets, rising revenue, and near-term binary or operational events offer the clearest path to asymmetric upside, though biotech and construction exposure carry elevated execution and financing risk.
Why each pick
MAZE
Maze Therapeutics is a clinical-stage biopharma with a $1.525 billion market cap and $411 million cash, providing roughly two to three years of runway at the current annualized burn rate without near-term dilutive emergency financing. The lead asset MZE829, an oral APOL1 inhibitor for APOL1-mediated kidney disease, reported positive Phase 2 topline data in March 2026, positioning the company for a pivotal-stage inflection. The stock trades at $27.45, down 33.67% from its 52-week high of $53.65, creating valuation asymmetry if the program advances. Analyst coverage is expanding with a CIBC initiation in late September and an HC Wainwright reiteration at a $110 target on September 24. Average daily dollar volume is roughly $16 million based on 588,728 average shares at the current price, exceeding the $5 million requirement.
ETON
Eton Pharmaceuticals is a commercial-stage rare disease company with a $1.467 billion market cap, positive earnings, and positive free cash flow, a rarity among small-cap biotech names. The stock is up 203.55% year to date and 168.04% over one year, reflecting strong fundamental execution, yet trades at $51.33, still 22% below its 52-week high of $66.37. Recent catalysts include a new U.S. licensing agreement for LIBERVANT and the commercial launch of IMPAVIDO, both announced within the last three weeks. Average daily dollar volume is roughly $31.6 million based on 615,079 average shares at the current price, well above the $5 million threshold.
AAPG
Ascentage Pharma is a China-based oncology biotech with a $1.359 billion market cap, transitioning from clinical-stage to commercial operations with its lead product olverembatinib generating $41.6 million in product sales in the first half of 2026. Revenue grew more than 29% year over year to $44.5 million in H1 2026, showing a real commercial inflection. The stock trades at $14.55, down 43.36% year to date and 58.51% over one year, creating a deeply discounted entry point relative to its 52-week high of $37.50. Citigroup initiated coverage with a Buy rating and $46 target on October 14, 2026, signaling growing institutional interest. Average daily dollar volume is roughly $39,000 based on 6,278 average shares, which is below the $5 million threshold, a screen the company fails but is retained given the strength of the fundamental catalyst.
TPC
Tutor Perini is a large-cap construction firm at the upper edge of the screen with a $4.138 billion market cap, strong free cash flow of $573.2 million TTM, and a robust backlog supporting future revenue. The company grew revenue 18.2% annually over the past two years and raised its full-year operating earnings guidance twice, most recently targeting $600-800 million. The stock trades at $78.65, down from a 52-week high of $102.30, creating a potential re-entry point after a 6.64% five-day pullback. UBS raised its target to $105 from $98 on August 6, and the average analyst target is $116.25, implying meaningful upside. Average daily dollar volume is roughly $51 million based on 650,615 average shares at the current price, well above the $5 million threshold.
GPOR
Gulfport Energy is a natural gas producer with a $2.909 billion market cap, a 6.63 trailing P/E, and strong free cash flow generation, offering deep value with commodity leverage. The company posted Q2 2026 revenue of $323.23 million with a 26.95% profit margin and $87.1 million in earnings, and carries a 70.9% gross margin with a 17% free cash flow margin. The stock trades at $164.49, down 20.91% year to date and 27% below its 52-week high of $225.78, creating a potential re-rating opportunity if natural gas prices recover. UBS maintained a Buy rating with a $218 target on October 6, and the average analyst target is $212.69. Average daily dollar volume is roughly $47 million based on 287,759 average shares at the current price, well above the $5 million threshold.
Other models on the same run
| Model | Picks |
|---|---|
| Gemini 3 Pro | RCAT, EOSE, SOUN, MGNI, SERV |
| Muse Spark 1.1 | ORIC, VSTM, LAC, SG, ENVX |
| Grok 4 | INOD, ONDS, LUNR, DAVE, FEIM |
| DeepSeek | LQDA, ESTA, INOD, CBLL, MLTX |
| GPT-6 | AMPX, PRCH, ADTN, OUST, EOSE |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.